{"preliminary_commentary":{"by_channel":{"x_thread":11,"podcast":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03009981\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["apalutamide"],["apalutamide","abiraterone"]],"indication":"high-risk biochemically relapsed castration-sensitive prostate cancer","name":"PRESTO","nct_id":"NCT03009981","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=presto-nct03009981. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients will receive degarelix OR leuprolide with bicalutamide.","label":"Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide","type":"ACTIVE_COMPARATOR"},{"description":"Patients will receive apalutamide and either degarelix OR leuprolide. Patients on this arm will NOT take bicalutamide at any point in the treatment course.","label":"Arm B: Degarelix/Apalutamide","type":"EXPERIMENTAL"},{"description":"Patients will receive apalutamide and abiraterone acetate, in addition to either degarelix OR leuprolide. Patients on this arm will NOT take bicalutamide at any point in the treatment course.","label":"Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone","type":"EXPERIMENTAL"}],"collaborators":["Janssen Research & Development, LLC"],"completion_date":{"date":"2025-06-25","type":"ACTUAL"},"conditions":["Prostate Cancer"],"enrollment":{"count":503,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Apalutamide","otherNames":["Erleada"],"type":"DRUG"},{"name":"LHRH Analogue","otherNames":["Degarelix (Firmagon)","Leuprolide (Lupron) and Bicalutamide"],"type":"DRUG"},{"name":"Abiraterone Acetate","otherNames":["Zytiga"],"type":"DRUG"},{"name":"Prednisone","otherNames":["Deltasone"],"type":"DRUG"}],"last_update":"2026-11-09","lead_sponsor":"Alliance Foundation Trials, LLC.","official_title":"A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2025-06-25","type":"ACTUAL"},"primary_outcomes":[{"measure":"PSA Progression-free Survival in the Intent-to-treat Population","timeFrame":"36 months"}],"references":[{"citation":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.","pmid":"25559415","type":"BACKGROUND"},{"citation":"Zietman AL, Chung CS, Coen JJ, Shipley WU. 10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study. J Urol. 2004 Jan;171(1):210-4. doi: 10.1097/01.ju.0000100980.13364.a6.","pmid":"14665878","type":"BACKGROUND"},{"citation":"Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016 Jul;70(1):106-119. doi: 10.1016/j.eururo.2016.02.028. Epub 2016 Mar 17.","pmid":"26996659","type":"BACKGROUND"},{"citation":"Zelefsky MJ, Ben-Porat L, Scher HI, Chan HM, Fearn PA, Fuks ZY, Leibel SA, Venkatraman ES. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol. 2005 Feb 1;23(4):826-31. doi: 10.1200/JCO.2005.02.111.","pmid":"15681527","type":"BACKGROUND"},{"citation":"Qu Y, Dai B, Ye D, Kong Y, Chang K, Jia Z, Yang X, Zhang H, Zhu Y, Shi G. Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer. Sci Rep. 2015 Jan 7;5:7654. doi: 10.1038/srep07654.","pmid":"25563505","type":"BACKGROUND"},{"citation":"Gershon RC, Rothrock N, Hanrahan R, Bass M, Cella D. The use of PROMIS and assessment center to deliver patient-reported outcome measures in clinical research. J Appl Meas. 2010;11(3):304-14.","pmid":"20847477","type":"BACKGROUND"},{"citation":"Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. J Urol. 2024 Apr;211(4):526-532. doi: 10.1097/JU.0000000000003890. Epub 2024 Feb 29.","pmid":"38421252","type":"DERIVED"},{"citation":"Aggarwal R, Heller G, Hillman DW, Xiao H, Picus J, Taplin ME, Dorff T, Appleman L, Weckstein D, Patnaik A, Bryce A, Shevrin D, Mohler J, Anderson D, Rao A, Tagawa S, Tan A, Halabi S, Dooley K, O'Brien P, Chen R, Ryan CJ, Eggener SE, Morris MJ; EORTC-55994 Study Group. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). J Clin Oncol. 2024 Apr 1;42(10):1114-1123. doi: 10.1200/JCO.23.01157. Epub 2024 Jan 23.","pmid":"38261983","type":"DERIVED"}],"start_date":{"date":"2017-03-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT03009981"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/presto-nct03009981"}